Review reveals regenerative benefits of mesenchymal stromal cells in epidermolysis bullosa, highlighting cell-free extracellular vesicles and targeted delivery as key future avenues.
Epidermolysis bullosa (EB) is a group of inherited mucocutaneous disorders. Mesenchymal stromal cells (MSCs) are non-hematopoietic self-renewing, multipotent cells that are a promising therapeutic avenue for EB, given their ability to home to injury, low immunogenicity, and demonstrated wound-healing, anti-fibrotic, and pro-collagen effects. This review article synthesizes the current literature and advancement on MSC therapy in EB, and highlights the potential to optimize their use, including exploring MSC-derived extracellular vesicles as a potential cell-free therapy. Innovative delivery methods can also improve the accessibility and effectiveness of MSC therapies by providing localized treatment, minimizing systemic side effects, and increasing patient comfort.
No takes yet. Share an insight, caveat, or question.
Sia et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: